论文部分内容阅读
目的探讨重组人血管内皮抑制素(endostar,商品名恩度)联合伊立替康+亚叶酸钙+5-FU(FOLFIRI)方案抑制小鼠结肠癌生长及肝转移的作用。方法 40只BALB/c小鼠通过脾脏注射肿瘤细胞法建立结肠癌肝转移模型,按随机数字表法分为:①模型对照组;②恩度治疗组;③FOLFIRI组;④恩度联合FOLFIRI组(n=10)。模型建立的第2天开始按照制定的给药方案腹腔注射给药。第21天观察、比较各组小鼠脾脏种植瘤的体积,检测种植瘤的凋亡指数(apoptotic index,AI)、肿瘤微血管密度(microvessel dencity,MVD)和血清中的VEGF浓度以及肝脏转移瘤的情况。结果与模型对照组相比,恩度治疗组、FOLFIRI组、恩度联合FOLFIRI组脾脏种植瘤的体积、微血管密度、VEGF含量、肝脏转移瘤数目均减小(P<0.05),脾脏种植瘤的AI升高(P<0.05)。与恩度联合FOLFIRI组相比,恩度治疗组、FOLFIRI组脾脏种植瘤的体积、微血管密度、VEGF含量、肝脏转移瘤数目增大(P<0.05),脾脏种植瘤的AI减小(P<0.05)。结论恩度联合FOLFIRI可以促进结肠癌的凋亡,抑制结肠癌的生长及肝转移。
Objective To investigate the inhibitory effect of recombinant human endostar (Endostar) combined with irinotecan + leucovorin + 5-FU (FOLFIRI) on colon cancer growth and liver metastasis in mice. Methods Forty BALB / c mice were randomly divided into three groups: ① model control group; ② Endostar-treated group; ③ FOLFIRI group; ④ Endostar combined with FOLFIRI group n = 10). On the second day after the model was established, it was administered intraperitoneally according to the established dosing schedule. On the 21st day, the volume of spleen implanted tumor in each group was compared, the implanted tumor’s apoptotic index (AI), microvessel dencity (MVD) and serum VEGF concentration were detected, and liver metastases Happening. Results Compared with the model control group, the volume, the microvessel density, the VEGF content and the number of metastatic liver tumors in the spleen of Ende treatment group, FOLFIRI group and Endo combined with FOLFIRI group were decreased (P <0.05) AI increased (P <0.05). Compared with the enrolled FOLFIRI group, the volume, the microvessel density, the VEGF content and the number of liver metastases in the enamel treated group and the FOLFIRI group increased (P <0.05), and the AI in the spleen implanted tumor decreased (P < 0.05). Conclusion Endood combined with FOLFIRI can promote colon cancer apoptosis, inhibit colon cancer growth and liver metastasis.